The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HIMS | +101.19% | +365.75% | +36.03% | +404% |
| S&P | +14.5% | +93.32% | +14.09% | +123% |
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
New products are coming to the Hers platform.
Investors generally aren't fond of C-suite changes in relatively young businesses.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $544.83M | 72.6% |
| Gross Profit | $349.71M | 62.5% |
| Gross Margin | 64.19% | -4.0% |
| Market Cap | $11.16B | 157.3% |
| Market Cap / Employee | $6.82M | 0.0% |
| Employees | 1.6K | 56.5% |
| Net Income | $42.51M | 219.7% |
| EBITDA | $43.42M | 183.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.12B | 769.8% |
| Accounts Receivable | $6.74M | 21.3% |
| Inventory | 141.8 | 249.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.04B | 10480.8% |
| Short Term Debt | $3.14M | 91.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 16.42% | 12.3% |
| Return On Invested Capital | -10.19% | 4.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$71.24M | -249.8% |
| Operating Free Cash Flow | -$20.92M | -139.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 42.61 | 45.21 | 43.01 | 62.39 | -76.89% |
| Price to Book | 11.03 | 11.97 | 13.69 | 20.29 | 61.48% |
| Price to Sales | 3.49 | 3.94 | 4.08 | 6.36 | 43.11% |
| Price to Tangible Book Value | 17.07 | 18.64 | 20.36 | 28.72 | 43.13% |
| Price to Free Cash Flow TTM | 28.94 | 29.35 | 30.97 | 109.91 | 107.52% |
| Enterprise Value to EBITDA | 148.01 | 191.94 | 106.17 | 292.50 | -1.08% |
| Free Cash Flow Yield | 3.5% | 3.4% | 3.2% | 0.9% | -51.81% |
| Return on Equity | 26.3% | 30.7% | 36.8% | 41.9% | 688.84% |
| Total Debt | $11.36M | $11.35M | $63.38M | $1.04B | 9001.42% |
Motley Fool analysts take a look.
The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime.
Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
